Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review

Bhagat, Priyanka; Vij, Mukul; Raju, Lexmi Priya; Gowrishankar, Gowripriya; Menon, Jagadeesh; Shanmugam, Naresh; Kaliamoorthy, Ilankumaran; Rammohan, Ashwin; Rela, Mohamed

doi:10.3390/diagnostics13233524

Cited by 3 publications

(1 citation statement)

References 206 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatoblastomas (HBs) and pediatric hepatocellular carcinomas (HCCs) collectively constitute approximately 80% of primary malignant liver tumors in children and adolescents, respectively. HBs are more common than HCCs but, from a prognostic point of view, the prognosis for pediatric HCC is dismal, with a 5-year event-free survival of <30%, in stark contrast to HB’s >80% ( 142 , 143 ).…”

Section: Modeling the Solid-pediatric Tumors: Organoids As Tool To Un...mentioning

confidence: 99%

Organoids as a new approach for improving pediatric cancer research

Lampis,

Galardi,

Di Paolo

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

A key challenge in cancer research is the meticulous development of models that faithfully emulates the intricacies of the patient scenario, with emphasis on preserving intra-tumoral heterogeneity and the dynamic milieu of the tumor microenvironment (TME). Organoids emerge as promising tool in new drug development, drug screening and precision medicine. Despite advances in the diagnoses and treatment of pediatric cancers, certain tumor subtypes persist in yielding unfavorable prognoses. Moreover, the prognosis for a significant portion of children experiencing disease relapse is dismal. To improve pediatric outcome many groups are focusing on the development of precision medicine approach. In this review, we summarize the current knowledge about using organoid system as model in preclinical and clinical solid-pediatric cancer. Since organoids retain the pivotal characteristics of primary parent tumors, they exert great potential in discovering novel tumor biomarkers, exploring drug-resistance mechanism and predicting tumor responses to chemotherapy, targeted therapy and immunotherapies. We also examine both the potential opportunities and existing challenges inherent organoids, hoping to point out the direction for future organoid development.

show abstract

Section: Modeling the Solid-pediatric Tumors: Organoids As Tool To Un...mentioning

confidence: 99%

Organoids as a new approach for improving pediatric cancer research

Lampis,

Galardi,

Di Paolo

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Une fuite en masse

Gaschignard,

Gotchac,

Lavrand

et al. 2024

Perfectionnement en Pédiatrie

View full text Add to dashboard Cite

Liver transplantation for pediatric liver malignancies

Sakamoto,

Harikrishnan,

Uchida

et al. 2024

Liver Transplantation

View full text Add to dashboard Cite

In the last few decades, collaboration between the international pediatric oncology groups has resulted in significant improvement in survival after liver transplantation (LT) for pediatric liver tumors, and LT has become the accepted standard of care for unresectable pediatric liver tumors – either living donor liver transplantation (LDLT) or deceased donor liver transplantation (DDLT). Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the common pediatric liver malignancies treated by LT, and LT is now the accepted treatment modality for unresectable non-metastatic cases. The long-term survival rate is more than 80% in HB transplants. Furthermore, with the advent of LDLT, the waitlist mortality, availability of a better graft quality with shorter ischemic times, and performance of LT with the appropriate timing between chemotherapy have all improved. Up to 80% of pediatric HCCs are unresectable, and studies have shown that LT for pediatric HCC has better outcomes than liver resection. Furthermore, LT has also shown better results than liver resection for cases of HCC not meeting Milan criteria. Given the rarity of pediatric liver malignancies and challenges in optimal management, a multidisciplinary treatment approach, research models building on what is already known, and consideration of newer treatment modalities are required for further improving the treatment of pediatric liver malignancies.

show abstract

Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review

Cited by 3 publications

References 206 publications

Organoids as a new approach for improving pediatric cancer research

Organoids as a new approach for improving pediatric cancer research

Une fuite en masse

Liver transplantation for pediatric liver malignancies

Contact Info

Product

Resources

About